By Barbara Obstoj-Cardwell. Editor
M&A news featured again last week, first with Japan’s Ono Pharmaceutical announcing a $2.4 billion takeover of US oncology focused Deciphera Pharmaceuticals, and then Swiss pharma giant Novartis revealing that is acquiring US biotech start-up Mariana Oncology for up to $1.75 billion to expand its radioligand therapy portfolio. Also of note, Italy’s Newron Pharmaceuticals released positive new Phase II/III data for its schizophrenia candidate evenamide. And, US pharma giant Pfizer presented strong first-quarter 2024 financial results, despite significant loss of revenue from covid-related products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze